Liver transplantation for Wilson disease: a spectrum from acute liver failure to Neuro-Wilson Authors: Saad Alghamdi, Dimitri A Raptis, Ibrahim Alomar, Wejdan Alotaibi, Abeer Alabdullah, Bandar Aljudaibi, Ali Albenmousa, Khalid Bzeizi, Saleh A Alqahtani, Dieter C Broering, Waleed Al-Hamoudi Published: 2026 ABSTRACT AbstractIntroductionWilson disease (WD) is a rare autosomal recessive disorder of copper metabolism presenting with acute liver failure, cirrhosis, or neurologic involvement. Liver transplantation (LT) is the definitive treatment; however, data remain limited, particularly from regions reliant on living donor LT (LDLT).MethodsWe retrospectively analyzed a prospectively collected transplant database, identifying all patients (≥ 14 years) who underwent LT for WD between January 2001 and December 2023. Data on demographics, LT indications, disease characteristics, pre-transplant therapy, complications, and outcomes were collected. Survival was assessed using Kaplan-Meier methods, and neurologic outcomes from clinical documentation.ResultsForty-one patients underwent LT for WD (median age: 23 years; 51.2% female). Ascites was present in 68.4%, encephalopathy in 32.4%, and hepatocellular carcinoma in 5.1%. Acute liver failure was the initial presentation in 17.9%. LDLT comprised 53.7%. Acute cellular rejection occurred in 29.7% but was manageable; no patient required re-transplantation. Neurologic involvement was present in 17.1%, with 71% improving post-LT. One-, five-, and ten-year survival rates were 94%, 94%, and 82%.ConclusionLT for WD yields excellent long-term survival. Neurologic improvement occurred in most Neuro-Wilson patients, supporting LT even in neurologically affected cases. LDLT plays a crucial role in regions with limited deceased donors.Keywords: Acute Liver Failure, Graft Rejection, Liver Transplantation, Living Donors, and Wilson Disease Introduction Wilson disease (WD) is a rare autosomal recessive disorder of copper metabolism caused by homozygous or compound heterozygous mutations in the ATP7B gene on chromosome 13. The marked reduction in biliary excretion of copper and subsequent failure in its incorporation into apoceruloplasmin leads to excess copper deposition in vital organs, such as the liver, brain, kidneys, and cornea [1]. The clinical expression of WD is highly heterogeneous, typically manifesting in childhood or adolescence, although diagnosis may occasionally be delayed until adulthood. Historically, WD was estimated to affect approximately 30 individuals per million; however, more recent studies suggest a higher prevalence, likely due to increased awareness and expanded genetic screening [2, 3]. Hepatic involvement is often one of the initial clinical manifestations and may range from asymptomatic hepatomegaly to chronic liver disease, decompensated cirrhosis, or acute hepatic failure. Approximately 3% of all acute liver failure (ALF) cases are attributed to WD, characterized by Coombs-negative hemolytic anemia, encephalopathy, and coagulopathy [4]. Conversely, neurological symptoms, such as dysarthria, dystonia, tremors, and gait disturbances, may predominate in adolescent and adult patients, particularly in those with delayed diagnosis [5]. Initial management of WD focuses on pharmacologic therapies using chelating agents (penicillamine, trientine) and zinc salts to reduce gastrointestinal copper absorption. However, despite optimal medical therapy, a subset of patients progress to advanced liver disease. Liver transplantation (LT) remains the definitive treatment for such cases with excellent long-term outcomes. LT not only restores hepatic function but also corrects the underlying copper metabolism defect, thereby halting disease progression. However, the role of LT in patients with neurological manifestations remains debated due to concerns over irreversible neurodegeneration, despite emerging reports of potential neurological stabilization or improvement post-transplantation. Analysis of the United Network for Organ Sharing (UNOS) registry from 1987 to 2016 identified only 671 liver transplants performed for WD, 515 in adults and 156 in children, emphasizing the rarity of the condition, even in large national databases. These limited numbers highlight the critical value of single-center series in expanding the evidence base and exploring region-specific experiences, particularly in areas with high volumes of living donor LT (LDLT) [6]. In this study, we present a comprehensive analysis of patients with Wilson disease who underwent liver transplantation at a high-volume transplant center over more than two decades. The primary aim was to evaluate long-term post-transplant outcomes across the spectrum of disease presentation, including acute liver failure, chronic liver disease, and neurologic involvement. Methods From our prospectively collected database, we obtained data on patients who underwent LT at King Faisal Specialist Hospital & Research Center (KFSH&RC), Riyadh, Saudi Arabia, from January 2001 to December 2023. We included all patients who underwent liver transplantation for Wilson disease (WD). Since the disease is very rare, we included all patients who were ≥ 14 years old at the time of transplantation to focus on adolescent and adult presentations, as pediatric WD cases (< 14 years) were managed separately in our institution and may have distinct clinical profiles. Diagnosis of WD was established using a combination of clinical, biochemical, and genetic criteria consistent with the Leipzig scoring system [4]. All patients had a Leipzig score ≥ 4, incorporating low ceruloplasmin (< 200 mg/L), elevated 24-hour urinary copper (> 1.6 µmol/day), presence of Kayser-Fleischer (KF) rings, hemolytic anemia, and/or ATP7B mutations were tested. In cases with positive autoimmune markers (e.g., ANA or ASMA), WD was differentiated from autoimmune hepatitis through copper studies and response to chelation therapy or genetic confirmation. We collected data on demographics, LT indications, treatment prior to LT, and survival outcomes. Demographic data included age, gender, and body mass index (BMI). We also collected data related to WD, such as results of genetic testing, presence of Kayser-Fleischer rings on clinical examination, ceruloplasmin levels at presentation, 24-hour urine copper levels prior to transplantation, presence of hemolysis at the time of transplantation, and medical therapy. Furthermore, we obtained information on various disease presentations, including decompensated liver disease, acute liver failure, and the presence of neurologic manifestations of WD (Neuro-Wilson). For the latter, we assessed changes in neurological manifestations post-LT based on clinical documentation from neurology consultations, including descriptions of symptoms such as dystonia, tremors, or gait disturbances. Transplantation-related variables included the type of donor (living liver donor vs. deceased brain-dead [DBD]) and postoperative complications. It is important to note that all deceased donors were DBD. Outcomes of interest were patient and graft survival. Statistical method Continuous variables were compared using the Student’s t, Mann-Whitney U, one-way ANOVA, or the Kruskal-Wallis H tests, where appropriate. Differences among proportions were compared using the Fisher Exact or the Pearson χ2 tests, where appropriate. Survival analysis was performed using the Kaplan-Meier method, with differences assessed by the log-rank test. Multivariable binary logistic regression was used to investigate overall morbidity, i.e., the complication rate of any severity (Clavien-Dindo Grade ≥ 1). A p-value of less than 0.05 was considered statistically significant. Statistical analysis was performed using R version 3.3.2 (R Core Team, GNU GPL v2 License), R Studio version 1.0.44 (RStudio, Inc. GNU Affero General Public License v3, Boston, MA, 2016), with the graphical user interface (GUI) rBiostatistics.com (rBiostatistics.com, London, UK, 2017). This study was conducted in accordance with the STROCSS (Strengthening the Reporting of Cohort Studies in Surgery) criteria to ensure appropriate methodological rigor and ethical standards in reporting [7]. Ethics statement The study was approved by the Institutional Review Board (IRB) at King Faisal Specialist Hospital and Research Centre (KFSHRC), Riyadh, Saudi Arabia (IRB approval number: RAC 2121012). It was conducted in accordance with the Declaration of Helsinki, local guidelines, IRB recommendations, and institutional regulations. Regarding the Ethics approval and consent to participate section, due to the retrospective nature of the study, the need to obtain informed consent to participate was waived by the IRB at King Faisal Specialist Hospital and Research Centre (KFSHRC), Riyadh, Saudi Arabia. Data were accessed on 13/03/2024 from the institutional liver transplant registry by authorized study investigators. While the dataset included coded patient identifiers for linkage and validation purposes, all analyses were performed on de-identified data to ensure patient confidentiality. Results A total of 41 patients underwent LT for WD at our center between 2001 and 2023. The median age at diagnosis was 21 years (IQR 16–27.5), and the median age at transplantation was 23 years (IQR 18–33). Females accounted for 51.2% of the cohort, and the mean BMI was 22.3 ± 4.3 kg/m². The median MELD score at transplantation was 21.5. Acute liver failure (ALF) was the initial presentation in 17.9% of patients, and 17.1% had evidence of hemolysis at the time of listing. Genetic testing for ATP7B was performed in 25.6% of patients, all of whom had homozygous pathogenic variants. Kayser–Fleischer (KF) rings were documented in 60% of those examined (9 out of 15 patients). The median ceruloplasmin level at diagnosis was 80 mg/L (IQR 51.3–131.8), and the median 24-hour urinary copper excretion was 7.2 µmol/day (IQR 2.4–19.7). Baseline demographics and clinical characteristics of patients with Wilson Disease were summarized in Table 1. Table 1Patients’ characteristicsParametersOverall41 (100%)Age, median at diagnosis (IQR), years21 (16–27.5)Age, median at transplantation (IQR), years23 (18–33)Female sex, n (%)21 (51.2)BMI, mean (SD) kg/m222.33 (4.32)MELD at transplantation, median21.5 (17–32)Acute liver failure on presentation, n (%)7 (17.9)Hemolysis at presentation, n (%)7 (17.1)Genetic testing for ATP7B, n (%)10 (25.6)KF Ring, n (%)9/15 (60)Ceruloplasmin level, median at diagnosis (IQR)80 (51.25–131.75 mg/L)24 H urine copper level, median at diagnosis (IQR)7.2 (2.4–19.7)Chronic liver disease related complications Ascites, n (%)26 (68.4) Encephalopathy, n (%)12 (32.4) HCC, n (%)2 (5.1) CKD, n (%)6 (15.4) PA pressure > 25 based on TTE, n (%)8 (21.1)Treatment prior to liver transplantation Penicillamine, n (%)16 (41.0) Trientine, n (%)11 (28.2) Zinc, n (%)17 (43.6)Autoimmune markers ANA, n (%)11 (29.7) ASMA, n (%)17 (47.2) AMA, n (%)0Donor type Deceased donor, n (%)19 (46.3) Living donor, n (%)22 (53.7)IQR Interquartile range, BMI Body mass index, SD Standard Deviation, MELD Model for End-Stage Liver Disease, ATP7B ATPase Copper Transporting Beta, KF Kayser-Fleischer, HCC Hepatocellular Carcinoma, CKD Chronic Kidney Disease, PA Pulmonary Artery, TTE Transthoracic Echocardiogram, ANA Antinuclear Antibodies, ASMA Anti-smooth muscle Antibodies, AMA Anti-mitochondrial Antibodies Patients’ characteristics IQR Interquartile range, BMI Body mass index, SD Standard Deviation, MELD Model for End-Stage Liver Disease, ATP7B ATPase Copper Transporting Beta, KF Kayser-Fleischer, HCC Hepatocellular Carcinoma, CKD Chronic Kidney Disease, PA Pulmonary Artery, TTE Transthoracic Echocardiogram, ANA Antinuclear Antibodies, ASMA Anti-smooth muscle Antibodies, AMA Anti-mitochondrial Antibodies Complications of chronic liver disease were common. Ascites was present in 68.4% of patients, and hepatic encephalopathy in 32.4%. Hepatocellular carcinoma (HCC) was diagnosed in two patients (5.1%), both patients were within Milan criteria. Chronic kidney disease (CKD) was present in 15.4%, and elevated pulmonary artery pressure (defined as > 25 mmHg on transthoracic echocardiogram) was identified in 21.1% of patients. Regarding pre-transplant medical therapy, 41.0% had received penicillamine, 28.2% were treated with trientine, and 43.6% had been on zinc therapy. Autoimmune markers were notable, with antinuclear antibodies (ANA) detected in 29.7% of patients and anti-smooth muscle antibodies (ASMA) in 47.2%, while anti-mitochondrial antibodies (AMA) were negative in all patients. Pre-transplant complications, autoimmune markers, and medical therapies were summarized in Table 2. Table 2Transplantation outcomeOutcomeOverall41 (100%)Rejection Episode of acute cellular rejection, n (%)11/37 (29.7) Number of rejections = 1, n (%)6/16 (37.5) Number of rejections = 2, n (%)5/16 (31.3) Major post-operative events, n (%)10/39 (25.6)Re transplantation and survival Re-transplantation, n0 5-year patient survival, (%)(95) Transplantation outcome Living donor liver transplantation (LDLT) was performed in 53.7% of cases, while 46.3% received grafts from deceased donors. Acute cellular rejection occurred in 29.7% of patients (11 of 37), with six patients experiencing a single episode and five patients having two episodes. Major post-operative complications requiring ICU readmission or invasive intervention were observed in 25.6% (10 of 39). No patient required re-transplantation during the follow-up period. Two patients died during follow-up, with causes of death including septic shock and severe acute respiratory distress syndrome. Seven patients (17.1%) had documented neurologic involvement consistent with Neuro-Wilson at the time of transplantation. Among them, five (71%) demonstrated clinical improvement in neurological function following LT. Overall, patient and graft survival rates were excellent. At follow-up, 5-year survival rates was 94%. Kaplan–Meier survival curves for patient and graft survival are presented in Figs. 1 and 2, respectively. patient survival Graft survival Discussion In this large single-center cohort over two decades, we evaluated the outcome of 41 patients who underwent LT for WD across a broad clinical spectrum, ranging from acute liver failure to decompensated cirrhosis and neurologic involvement. Our findings highlight excellent long-term survival and even potential recovery in patients with neurologic manifestations. Our study showed excellent post-LT survival with 1-, 5-, and 10-year of 94%, 94%, and 82%, respectively. These results are consistent with, and in some cases, exceed previously reported outcomes in the literature. The analysis of the UNOS registry between 1987 and 2016 identified only 671 patients transplanted for WD, which shows how rare this indication is and the importance of focused reports from high-volume centers [6]. In our cohort, LDLT accounted for over half of the cases, highlighting the critical contribution of LDLT programs in expanding access to LT in regions where deceased organ availability remains limited. One particularly important observation was that five of the seven patients with Neuro-Wilson experienced neurological improvement following LT. Recent data from the French National WD Registry support this observation, demonstrating that LT led to significant neurologic improvement in 86% of patients with severe neurologic WD resistant to medical therapy [8]. While historically considered a relative contraindication due to concerns of irreversible brain injury, our findings contribute to the growing body of literature suggesting that LT can stabilize or improve neurological outcomes when performed early enough. This has significant implications for re-evaluating transplant candidacy criteria in patients with neurologically affected WD. Interestingly, nearly half of the patients exhibited positive autoimmune markers, with 29.7% testing positive for ANA and 47.2% for ASMA. None of our patients tested positive for anti-mitochondrial antibodies. This supports prior reports of autoimmune hepatitis-like presentations in WD and reinforces the need for careful diagnostic evaluation in young patients with abnormal liver enzymes and positive serologies [9]. In settings with high consanguinity or known familial cases, early genetic testing may aid in timely diagnosis and management. Our cohort also included two patients who developed HCC, a rare but recognized complication in WD-related cirrhosis [10]. Furthermore, the prevalence of extrahepatic complications-including chronic kidney disease (15.4%) and elevated pulmonary artery pressures (21.1%)-highlights the systemic nature of copper toxicity and the need for comprehensive pre-transplant evaluation [11, 12]. Acute cellular rejection occurred in approximately 30% of patients, which aligns with rates reported in other etiologies of liver disease [13]. All rejection episodes were successfully managed with immunosuppressive adjustment, and no patient required re-transplantation. While our study provides robust data on the outcomes of LT for WD, several limitations should be acknowledged. The retrospective nature is the primary limitation. Neurological outcomes were assessed based on clinical documentation rather than standardized neurocognitive testing, which may limit the objectivity of these findings. Subgroup analyses comparing outcomes between LDLT and DBD, as well as between ALF and patients with chronic liver disease related complications, were not performed due to the small sample size and the excellent overall outcomes Additionally, genetic testing was not performed in all patients. Despite these limitations, the study provides valuable insight into real-world outcomes of LT for WD in a region characterized by high living donor activity and limited published data. Conclusion LT for patients with WD is associated with excellent long-term survival, regardless of the clinical presentation at diagnosis. Importantly, our study showed that LT not only restores hepatic function but can also lead to significant improvement in neurological symptoms for those with Neuro-Wilson. It also highlights both the critical contribution of LDLT in expanding access to transplantation and the need for continued reporting from single-center experiences to strengthen the global evidence base for this rare disease. Abbreviations Wilson disease ATPase Copper Transporting Beta (the gene associated with Wilson disease) Acute Liver Failure Liver Transplantation United Network for Organ Sharing Living Donor Liver Transplantation King Faisal Specialist Hospital & Research Center Body Mass Index Kayser-Fleischer Deceased Brain-Dead Antinuclear Antibodies Anti-smooth muscle Antibodies Anti-mitochondrial Antibodies Interquartile Range Model for End-Stage Liver Disease Hepatocellular Carcinoma Chronic Kidney Disease Diabetes Mellitus Hypertension Standard Deviation Statistical Package for the Social Sciences Graphical User Interface General Public License Strengthening the Reporting of Cohort Studies in Surgery Intensive Care Unit Authors’ contributions The project was conceptualized by SA, SAA, and WA. Data curation was performed by IO, WA, and AA, while formal analysis was conducted by DA and AA. AA and KB led the investigation, and the methodology was developed by KB and BA. Project administration and supervision were provided by SA and WA. Resources were managed by DB and KB, and validation was handled by DB and SAA. The original draft was prepared by SA and WA, with KB and SAA contributing to the final review and editing process. All authors read and approved the final manuscript for submission. Funding None. Data availability Data available on request. Declarations Ethics approval and consent to participate The study was approved by the Institutional Review Board (IRB) at King Faisal Specialist Hospital and Research Centre (KFSHRC), Riyadh, Saudi Arabia (IRB approval number: RAC 2121012). The study was conducted in accordance with the Declaration of Helsinki and local institutional regulations. Due to the retrospective nature of the study and the use of de-identified data from the institutional liver transplant registry, the requirement for informed consent to participate was waived by the Institutional Review Board (IRB) at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. Consent for publication Not Applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Data available on request.